BACKGROUND: Nirmatrelvir/ritonavir (NMV/r) is indicated for the treatment of mild-to-
moderate COVID-19 in adults who are at high risk for progression to severe COVID-19 …

Background Uptake of coronavirus disease 2019 (COVID-19) bivalent vaccines and the oral
medication nirmatrelvir-ritonavir (Paxlovid) has remained low across the United States …

Objective To compare the effectiveness of Paxlovid vs. sotrovimab and molnupiravir in
preventing severe COVID-19 outcomes in non-hospitalised high-risk COVID-19 adult …

Background: In the EPIC-HR trial, nirmatrelvir plus ritonavir led to an 88% reduction in
hospitalization or death among unvaccinated outpatients with early COVID-19. Clinical …

Dear Editor, Since the first outbreak in late 2019, the RNA genome of SARS-CoV-2 has
been undergoing constant evolution. This is largely attributed to the viral polymerase that is …

Background: Even though worldwide death rates from coronavirus disease 2019 (COVID-
19) have decreased, the threat of disease progression and death for high-risk groups …

Background: Whether hospitalized patients benefit from COVID-19 oral antivirals is
uncertain. Objective: To examine the real-world effectiveness of molnupiravir and …

Provisional be done with caution. However, subgroup analyses stratified by those aged≥ 65
years and those aged< 65 years, as well as subgroup analyses stratified by risk factors for …

The coronavirus disease 2019 (COVID-19) pandemic has reached a turning point. The non-
pharmaceutical interventions for preventing COVID-19 are lifting. Vaccination uptake is …

Background Current guidelines recommend using nirmatrelvir-ritonavir for coronavirus
disease 2019 (COVID-19) treatment, but its potential drug interactions and contraindications …